Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Andrew Witty — who became UnitedHealth Group’s CEO in 2021 — is stepping down from the top post due to personal reasons after ...

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it ...

GlaxoSmithKline Pharmaceuticals, the Indian arm of UK-based GSK, reported a 35% year-on-year jump in consolidated net profit ...

GSK’s share price has fallen significantly in the past 12 months, but this could mean it looks a major bargain now, ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...